With the support of the EMA/ CVMP, the European Commission appears well on track with the process of drafting the delegated act (Art.146) on Annex II of the Regulation (EU) 2019/6. The scientific recommendations provided by EMA/CVMP on Annex II will require a variety of further guidance documents, which need to be adapted for the development of new and innovative products. Dr. Klaus Hellmann and Dr. Regina Wolf at Klifovet examine how the contents of Title IIa, Title III.8 and IV define new specific requirements to obtain marketing authorisations for non-immunological biological veterinary medicinal products (VMPs) and novel therapies.
- Environmental protection could benefit from ‘micro’ as well as ‘macro’ thinking ...
- Snake species from different terrains surrender surface secrets behind slithering success ...
- Forest elephants are now critically endangered – here’s how to count them ...
- Confirmed: Island gigantism and dwarfism result of evolutionary island rule ...
- Blow flies may be the answer to monitoring the environment non-invasively ...
